Geron Corp (GERN)

Jan 16, 2025, 1:46 PM EST - 1 day ago

Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales

Dec 19, 2024, 4:30 PM EST - 4 weeks ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2024, 6:36 AM EST - 5 weeks ago

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Dec 10, 2024, 9:00 AM EST - 5 weeks ago

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Dec 10, 2024, 9:00 AM EST - 5 weeks ago

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Nov 27, 2024, 9:00 AM EST - 7 weeks ago

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 21, 2024, 3:05 PM EST - 2 months ago

Geron: A Strong Launch And Financial Deals Make It Attractive

Nov 11, 2024, 4:30 PM EST - 2 months ago

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

Nov 11, 2024, 9:00 AM EST - 2 months ago

Geron to Participate in the Stifel 2024 Healthcare Conference

Nov 7, 2024, 1:01 PM EST - 2 months ago

Geron: A Post Earnings And Funding Announcement Assessment

Nov 7, 2024, 11:20 AM EST - 2 months ago

Geron Corporation (GERN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:01 AM EST - 2 months ago

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

Nov 7, 2024, 7:00 AM EST - 2 months ago

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 5, 2024, 9:00 AM EST - 2 months ago

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

Oct 15, 2024, 4:30 PM EDT - 3 months ago

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

Sep 23, 2024, 5:17 PM EDT - 4 months ago

Geron: Derisked And Highly Attractive After Approval

Sep 9, 2024, 4:15 PM EDT - 4 months ago

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 26, 2024, 7:30 AM EDT - 6 months ago

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Jul 23, 2024, 4:15 PM EDT - 6 months ago

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

Jul 18, 2024, 4:30 PM EDT - 6 months ago

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

Jun 7, 2024, 4:10 PM EDT - 8 months ago

Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers

Jun 7, 2024, 10:30 AM EDT - 8 months ago

Geron Corp stock opened 25% up on Friday: here's why

Jun 7, 2024, 7:49 AM EDT - 8 months ago

Very good news for Geron stock price: now what?

Jun 7, 2024, 6:04 AM EDT - 8 months ago

Geron shares surge after U.S. FDA approves blood disorder drug

Jun 6, 2024, 9:58 PM EDT - 8 months ago

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

May 23, 2024, 5:49 PM EDT - 8 months ago

Geron Corporation: A High-Risk Deal With A Good Chance Of Success

May 2, 2024, 7:00 AM EDT - 9 months ago

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 4:23 PM EDT - 9 months ago

Geron: FDA PDUFA Review With Continued Imetelstat Advancement

Apr 28, 2024, 4:39 AM EDT - 9 months ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA LYRA

Apr 25, 2024, 4:30 PM EDT - 9 months ago

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Apr 3, 2024, 4:30 PM EDT - 10 months ago

Geron to Participate at Upcoming Investor Conferences in April

Mar 19, 2024, 9:07 AM EDT - 10 months ago

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Mar 17, 2024, 8:31 AM EDT - 10 months ago

Can Geron Corporation maintain momentum following FDA's backing?

Mar 15, 2024, 11:50 AM EDT - 11 months ago

Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug

Mar 14, 2024, 3:54 PM EDT - 11 months ago

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Mar 14, 2024, 3:28 PM EDT - 11 months ago

Geron's blood disorder drug gets FDA advisers' backing

Mar 12, 2024, 9:44 AM EDT - 11 months ago

US FDA staff flags concerns about Geron's anemia treatment

Mar 5, 2024, 10:30 AM EST - 11 months ago

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Feb 28, 2024, 10:29 AM EST - 11 months ago

Geron Corporation (GERN) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:05 AM EST - 11 months ago

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 4:30 PM EST - 1 year ago

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Jan 12, 2024, 8:30 AM EST - 1 year ago

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Dec 11, 2023, 4:15 PM EST - 1 year ago

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Dec 6, 2023, 8:00 AM EST - 1 year ago

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Dec 4, 2023, 1:50 PM EST - 1 year ago

Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case

Dec 4, 2023, 5:00 AM EST - 1 year ago

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Nov 28, 2023, 8:00 AM EST - 1 year ago

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Nov 7, 2023, 4:30 PM EST - 1 year ago

Geron to Participate at Upcoming Investor Conferences in November

Nov 2, 2023, 1:05 PM EDT - 1 year ago

Geron Corporation (GERN) Q3 2023 Earnings Call Transcript